Eltrombopag is a thrombopoietin receptor (TpoR) agonist (EC₅₀ = 0.27 µM in a reporter assay) and an iron chelator (Erickson‐Miller et al.). Interaction between Eltrombopag and TpoR triggers proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes and increases platelet growth and production (Erickson‐Miller et al.).
DIFFERENTIATION
· Stimulates proliferation and differentiation of primary human CD34+ bone marrow cells into CD41+ megakaryocytes (Erickson‐Miller et al.).
DIFFERENTIATION
· Stimulates proliferation and differentiation of primary human CD34+ bone marrow cells into CD41+ megakaryocytes (Erickson‐Miller et al.).
未找到
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
未找到
Resources and Publications
Publications (1)
Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem cells (Dayton, Ohio) 2009 feb
Abstract
Eltrombopag is a first-in-class, orally bioavailable, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), which is being developed as a treatment for thrombocytopenia of various etiologies. In vitro studies have demonstrated that the activity of eltrombopag is dependent on expression of TpoR, which activates the signaling transducers and activators of transcription (STAT) and mitogen-activated protein kinase signal transduction pathways. The objective of this preclinical study is to determine if eltrombopag interacts selectively with the TpoR to facilitate megakaryocyte differentiation in platelets. Functional thrombopoietic activity was demonstrated by the proliferation and differentiation of primary human CD34(+) bone marrow cells into CD41(+) megakaryocytes. Measurements in platelets in several species indicated that eltrombopag specifically activates only the human and chimpanzee STAT pathways. The in vivo activity of eltrombopag was demonstrated by an increase of up to 100{\%} in platelet numbers when administered orally (10 mg/kg per day for 5 days) to chimpanzees. In conclusion, eltrombopag interacts selectively with the TpoR without competing with Tpo, leading to the increased proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes and increased platelet production. These results suggest that eltrombopag and Tpo may be able to act additively to increase platelet production.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
